ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pamvatamig

Also written as “MCLA-129” and “MCLA-129: 1500mg or 2000mg IV Q2W”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.

Drug pagePamvatamig: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since May 31, 20215 company-led studies, 4 open or runningNext primary completion: Apr 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Betta Pharmaceuticals44 open or runningphase 2since May 31, 2021May 31, 2021Apr 2028phase 2 · NCT06885840
Genmabits history only10 open or runningphase 2since Apr 9, 2021Apr 9, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Betta Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 31, 2021First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04930432 · 400 planned · China
  2. Aug 6, 2023Named pamvatamigINNProposed as its International Nonproprietary Name in WHO's List 129 · before, MCLA-129
  3. Aug 21, 2023Phase 1 study in Non-Small Cell Lung Cancer、EGFR Sensitive MutationNCT06015568 · 172 planned · China
  4. Mar 14, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06885840 · 100 planned · China
  5. Jan 31, 2026Phase 2 study in Solid Advanced TumorNCT07448116 · 164 planned · China

Ahead

  1. Apr 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06885840
  2. Apr 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04930432
  3. Nov 4, 2028Primary completion: phase 1 study in Non-Small Cell Lung Cancer、EGFR Sensitive MutationNCT06015568
  4. Feb 1, 2029Primary completion: phase 2 study in Solid Advanced TumorNCT07448116

TargetBeta

EGFR →MET →read by rule
“A human bispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

All 4 Betta Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07448116Solid Advanced Tumor · China2RecruitingFeb 1, 2029164
NCT06885840Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingApr 2028100
NCT06015568Non-Small Cell Lung Cancer、EGFR Sensitive Mutation · China1Not yet recruitingNov 4, 2028172
NCT04930432Carcinoma, Non-Small-Cell Lung · China2RecruitingApr 30, 2028400

How it is read

Names in the registry

  • “MCLA-129”, 4 entries
  • “MCLA-129: 1500mg or 2000mg IV Q2W”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.